340B Health

340B Insight Podcast

340B Insight

340B Insight is 340B Health’s podcast, providing our members and supporters with timely news updates and discussion around the 340B drug pricing program. The podcast enables listeners to stay current and expand their knowledge of 340B to help them serve their patients and communities and remain compliant with rules and requirements. New episodes are published twice per month and include news update segments and in-depth interviews with leading experts including health care practitioners, policy and legal experts, public policymakers, and our expert staff.

Listen and Subscribe

Have a question or suggestion for 340B Insight? Email us at: podcast@340bhealth.org

Podcast sponsorship opportunities are available. Email to learn more: robin.hayes@340bhealth.org

Follow 340B Health on Twitter, Facebook, and LinkedIn



  • Episode 89: How New 340B Reporting Requirements Are Affecting Hospitals

    340B sits at an intersection where federal programs and state agencies come together. Maine, Minnesota, and Washington recently enacted new laws requiring hospitals to report 340B information to the states each year. What should health systems know about these new requirements? We speak with Danny Ackert, the director of state government relations at the Minnesota Hospital Association, to learn more about what these requirements look like in his state and what hospitals might expect in other states considering such reporting. (Transcript)

    Read more

  • Episode 88: Answering More of Your 340B Questions

    We are returning to a popular episode format we aired early last year, when we consulted with 340B Health’s expert staff to answer your most pertinent 340B questions. As we start another busy year for 340B, we help you prepare for the action by answering your questions about the Genesis court decision, 340B activity in state legislatures, Medicare Part B repayments, and more. (Transcript)

    Read more

  • Episode 87: Advice for 340B Hospitals Pursuing Health Equity

    The 340B drug pricing program can produce significant savings that hospitals can invest in more equitable care for underserved patients. What are some of the best ways for hospitals to use their savings in the pursuit of greater health equity? We sit down with Danielle McPherson, the executive director of managed care contracting and operations with Mercy Health, to discuss how one Mercy hospital uses 340B savings to close health care gaps in the St. Louis area. Danielle provides practical advice for how other hospitals can take their own integrated, collaborative, and formalized approaches to 340B and health equity. (Transcript)

    Read more

  • Episode 86: Major New Developments End an Exciting Year for 340B

    The past several months have seen several major developments in the world of 340B drug pricing. 340B Health President and CEO Maureen Testoni returns to the show to break down some of the most important recent 340B stories. (Transcript)

    Read more

  • Episode 85: How To Engage Your Leadership on 340B

    In July, Karen Bowling became the new chair of the 340B Health Board of Directors. The West Virginia native is the president and CEO of Princeton Community Hospital and executive vice president of government affairs for West Virginia University Health System (WVU Medicine).

    In this episode, Bowling discusses her clinical and leadership experience, her 340B advocacy and communications work, and her advice for getting hospital and health system leaders engaged on 340B. (Transcript)

    Read more

  • Episode 84: 340B in the States: 2023 State Legislative Recap and 2024 Outlook

    This week we are joined by Amanda Sellers Smith, legal counsel for 340B Health. Amanda tracks and responds to 340B state legislative and regulatory actions. She discusses recent developments in state-based legislation, including 340B reporting requirements, nondiscrimination prohibitions, and bans on drugmaker restrictions. She also looks ahead to what hospitals and their government relations departments can expect in 2024. Before the interview, we give an update on a set of unprecedented changes to a major drugmaker’s restrictive contact pharmacy policy, and we share the news that four of the five drugmakers that HRSA audited last fiscal year for 340B compliance received findings for overcharging covered entities. (Transcript)

    Read more